52 related articles for article (PubMed ID: 32401358)
1. STAT3 inhibition reduced PD-L1 expression and enhanced antitumor immune responses.
Jahangiri A; Dadmanesh M; Ghorban K
J Cell Physiol; 2020 Dec; 235(12):9457-9463. PubMed ID: 32401358
[TBL] [Abstract][Full Text] [Related]
2. Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling.
Bazhin AV; von Ahn K; Fritz J; Werner J; Karakhanova S
Front Immunol; 2018; 9():2129. PubMed ID: 30356906
[TBL] [Abstract][Full Text] [Related]
3. Combination of STAT3 inhibitor with Herceptin reduced immune checkpoints expression and provoked anti-breast cancer immunity: An in vitro study.
Jahangiri A; Ezzeddini R; Zounemat Kermani N; Bahrami F; Salek Farrokhi A
Scand J Immunol; 2023 Sep; 98(3):e13300. PubMed ID: 38441231
[TBL] [Abstract][Full Text] [Related]
4. Brain Metastases Are Regulated by Immuno-inflammatory Signaling Pathways Governed by STAT3, MAPK and Tumor Suppressor p53 Status: Possible Therapeutic Targets.
Zeller SL; Spirollari E; Dicpinigaitis AJ; Wainwright JV; Hanft SJ; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2024 Jan; 44(1):13-22. PubMed ID: 38160007
[TBL] [Abstract][Full Text] [Related]
5. The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1.
Erlichman N; Meshel T; Baram T; Abu Raiya A; Horvitz T; Ben-Yaakov H; Ben-Baruch A
Cells; 2023 Sep; 12(19):. PubMed ID: 37830552
[TBL] [Abstract][Full Text] [Related]
6. Arsenic up-regulates PD-L1 and enhances lung tumorigenesis through activation of STAT3 in alveolar epithelial type 2 cells.
Xu W; Cui J; Busayli AM; Zhang T; Chen G
Toxicol Appl Pharmacol; 2024 Jan; 482():116787. PubMed ID: 38101582
[TBL] [Abstract][Full Text] [Related]
7. Curcumin inhibits colon cancer malignant progression and promotes T cell killing by regulating miR-206 expression.
Tong Q; Wu Z
Clin Anat; 2024 Jan; 37(1):2-11. PubMed ID: 37191314
[TBL] [Abstract][Full Text] [Related]
8. Role of HDAC6-STAT3 in immunomodulatory pathways in Colorectal cancer cells.
Mardones C; Navarrete-Munoz C; Armijo ME; Salgado K; Rivas-Valdes F; Gonzalez-Pecchi V; Farkas C; Villagra A; Hepp MI
Mol Immunol; 2023 Dec; 164():98-111. PubMed ID: 37992541
[TBL] [Abstract][Full Text] [Related]
9. Exploring Natural Compounds Targeting PD-L1 and STAT3: Toxicogenomic Analysis, Virtual Screening, Molecular Docking, ADMET Evaluation, and Biological Activity Prediction.
Karakuş F; Kuzu B; Köstekci S; Tülüce Y
Curr Comput Aided Drug Des; 2024 May; ():. PubMed ID: 38808724
[TBL] [Abstract][Full Text] [Related]
10. Targeting STAT3 in Cancer Immunotherapy.
Zou S; Tong Q; Liu B; Huang W; Tian Y; Fu X
Mol Cancer; 2020 Sep; 19(1):145. PubMed ID: 32972405
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy.
Han R; Rao X; Zhou H; Lu L
Int J Nanomedicine; 2024; 19():4803-4834. PubMed ID: 38828205
[TBL] [Abstract][Full Text] [Related]
12. NKX2‑1 copy number alterations are associated with oncogenic, immunological and prognostic remodeling in non‑small cell lung cancer.
Luna HGC; Imasa MS; Juat N; Hernandez KV; Sayo TM; Cristal-Luna G; Asur-Galang SM; Bellengan M; Duga KJ; Buenaobra BB; De Los Santos MI; Medina D; Samo J; Literal VM; Sy-Naval S
Oncol Lett; 2024 Jul; 28(1):303. PubMed ID: 38774453
[TBL] [Abstract][Full Text] [Related]
13. Pathways and molecules for overcoming immunotolerance in metastatic gastrointestinal tumors.
Gan Q; Li Y; Li Y; Liu H; Chen D; Liu L; Peng C
Front Immunol; 2024; 15():1359914. PubMed ID: 38646539
[TBL] [Abstract][Full Text] [Related]
14. JAK/STAT3 signaling in cardiac fibrosis: a promising therapeutic target.
Jiang H; Yang J; Li T; Wang X; Fan Z; Ye Q; Du Y
Front Pharmacol; 2024; 15():1336102. PubMed ID: 38495094
[TBL] [Abstract][Full Text] [Related]
15. Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target.
Pellegrino M; Secli V; D'Amico S; Petrilli LL; Caforio M; Folgiero V; Tumino N; Vacca P; Vinci M; Fruci D; de Billy E
Front Immunol; 2024; 15():1356321. PubMed ID: 38420122
[TBL] [Abstract][Full Text] [Related]
16. Overcoming cancer risk in inflammatory bowel disease: new insights into preventive strategies and pathogenesis mechanisms including interactions of immune cells, cancer signaling pathways, and gut microbiota.
Zhang H; Shi Y; Lin C; He C; Wang S; Li Q; Sun Y; Li M
Front Immunol; 2023; 14():1338918. PubMed ID: 38288125
[TBL] [Abstract][Full Text] [Related]
17. Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice.
Liu L; Li H; Li P; Zhou R; Zhang Q; Liu T; Feng L
Iran J Pharm Res; 2023; 22(1):e134216. PubMed ID: 38116545
[TBL] [Abstract][Full Text] [Related]
18. Reconstitution of Natural Killer cells after allogeneic hematopoietic stem cell transplantation is facilitated by Huiyang-Guben decoction through activating the Smad7/Stat3 signal pathway.
Gao X; Wang Q; He H; Yang T; Zhang H; Zhao J; Yao X
Mol Cell Biochem; 2023 Nov; ():. PubMed ID: 37973706
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Na+/H+ exchanger (NHE) 7 by 5-(N-ethyl-N-isopropyl)-Amiloride displays anti-cancer activity in non-small cell lung cancer by disrupting cancer stem cell activity and downregulating PD-L1 expression.
Wang BY; Shen HT; Lee YL; Chien PJ; Chang WW
Am J Cancer Res; 2023; 13(10):4721-4733. PubMed ID: 37970357
[TBL] [Abstract][Full Text] [Related]
20. Solamargine induces apoptosis of human renal carcinoma cells via downregulating phosphorylated STAT3 expression.
Huang S; Sun M; Ren Y; Luo T; Wang X; Weng G; Cen D
Oncol Lett; 2023 Nov; 26(5):493. PubMed ID: 37854861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
